{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:18:11Z","timestamp":1772723891101,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.rcsop.2026.100711","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:53:52Z","timestamp":1769734432000},"page":"100711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Class-level drug safety surveillance in hospital practice: A pharmacovigilance analysis of 84 therapeutic subclasses from a South Asian tertiary care center"],"prefix":"10.1016","volume":"21","author":[{"given":"Abdullah","family":"Umer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam Khan","family":"Mohmand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naimal Mouzam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainan","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sher M.","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcsop.2026.100711_bb0005","author":"World Health Organization"},{"issue":"7","key":"10.1016\/j.rcsop.2026.100711_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055551","article-title":"Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions","volume":"12","author":"Osanlou","year":"2022","journal-title":"BMJ Open"},{"issue":"379","key":"10.1016\/j.rcsop.2026.100711_bb0015","article-title":"Spontaneous reporting of post-market safety signals: what evidence should support regulatory action?","author":"Dhodapkar","year":"2022","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.rcsop.2026.100711_bb0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s43441-022-00415-y","article-title":"A systematic review of pharmacovigilance systems in developing countries using the WHO pharmacovigilance indicators","volume":"56","author":"Garashi","year":"2022","journal-title":"Ther Innov Regul Sci"},{"issue":"8","key":"10.1016\/j.rcsop.2026.100711_bb0025","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/bcp.15791","article-title":"Improving the spontaneous reporting of suspected adverse drug reactions: an overview of systematic reviews","volume":"89","author":"Routledge","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rcsop.2026.100711_bb0030","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.rcsop.2026.100711_bb0035","author":"Uppsala Monitoring Centre"},{"issue":"5","key":"10.1016\/j.rcsop.2026.100711_bb0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.rcsop.2026.100711_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"10.1016\/j.rcsop.2026.100711_bb0050","author":"European Medicines Agency"},{"issue":"8","key":"10.1016\/j.rcsop.2026.100711_bb0055","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.3390\/ijerph19084447","article-title":"Comparison of patient adverse drug reaction reporting systems in nine selected countries","volume":"19","author":"Worakunphanich","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"10.1016\/j.rcsop.2026.100711_bb0060","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rcsop.2026.100711_bb0065","series-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update [Internet]","author":"World Health Organization","year":"2022"},{"issue":"1","key":"10.1016\/j.rcsop.2026.100711_bb0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bjae.2023.10.005","article-title":"Neuromuscular block management: evidence-based principles and practice","volume":"24","author":"Rodney","year":"2024","journal-title":"BJA Educ"},{"issue":"4","key":"10.1016\/j.rcsop.2026.100711_bb0075","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s12325-023-02436-x","article-title":"Aminoglycoside-related nephrotoxicity and ototoxicity in clinical practice: a review of pathophysiological mechanism and treatment options","volume":"40","author":"Le","year":"2023","journal-title":"Adv Ther"},{"issue":"25","key":"10.1016\/j.rcsop.2026.100711_bb0080","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1056\/NEJMra064928","article-title":"Infection in solid-organ transplant recipients","volume":"357","author":"Fishman","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.rcsop.2026.100711_bb0085","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/PTS.0000000000000696","article-title":"Inpatient respiratory arrest associated with sedative and analgesic medications: impact of continuous monitoring on patient mortality and severe morbidity","volume":"17","author":"McGrath","year":"2021","journal-title":"J Patient Saf"},{"issue":"2","key":"10.1016\/j.rcsop.2026.100711_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00280-024-04693-1","article-title":"Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing","volume":"94","author":"Murzyn","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.1016\/j.rcsop.2026.100711_bb0095","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/jpp\/rgab102","article-title":"Narrow therapeutic index drugs: clinical pharmacology perspective","volume":"73","author":"Habet","year":"2021","journal-title":"J Pharm Pharmacol"},{"issue":"9","key":"10.1016\/j.rcsop.2026.100711_bb0100","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/pds.3622","article-title":"Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database","volume":"23","author":"de Boissieu","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.rcsop.2026.100711_bb0105","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1574886318666230428144120","article-title":"Current scenario and future prospects of adverse drug reactions (ADRs) monitoring and reporting mechanisms in the rural areas of India","volume":"19","author":"Shukla","year":"2024","journal-title":"Curr Drug Saf"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276626000090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276626000090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:16:23Z","timestamp":1772720183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276626000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"alternative-id":["S2667276626000090"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2026.100711","relation":{},"ISSN":["2667-2766"],"issn-type":[{"value":"2667-2766","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Class-level drug safety surveillance in hospital practice: A pharmacovigilance analysis of 84 therapeutic subclasses from a South Asian tertiary care center","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2026.100711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100711"}}